The VOYAGE phase 2 trial demonstrated that etrasimod, an oral S1P receptor modulator, significantly reduces oesophageal eosinophilic inflammation and improves endoscopic findings in adults with eosinophilic oesophagitis, with a favorable safety profile over 52 weeks.